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The study of the liver as a lymphoid organ is a growing ﬁeld fueled by our better knowledge of the
different component of the immune system and how they orchestrate an immune-related response. The
liver have highly specialized mechanisms of immune tolerance, mainly because is continuously exposed
to microbial and environmental antigens, and dietary components from the gut. Accordingly, the liver
contains specialized lymphoid subpopulations acting as antigen-presenting cells. Growing evidences
show that the liver is also associated with obesity-associated diseases because of its immune-related
capacity to sense metabolic stress induced by nutritional surplus. Finally, the liver produces a pletora
of neo-antigens being the primary metabolic organ of the body. Common immune mechanisms play a
key pathogenetic role in most of acute and chronic liver diseases and in the rejection of liver allografts.
Any perturbations of liver-related immune functions have important clinical implications. This issue of
the Journal of Autoimmunity is focused on the more recent advances in our knowledge related to the loss
of liver tolerance, a paradox for a tolerogenic organ, that leads to overactivation of the innate and
adaptive immune response and the development of autoimmune liver diseases, such as autoimmune
hepatitis, primary biliary cirrhosis, and primary sclerosing cholangitis. The invited expert review articles
capture the underlying immunomolecular mechanisms of the development and progression of auto-
immune liver diseases, the novel ﬁeld of the immune-related “liver-gut” axis inﬂuences to the devel-
opment of liver autoimmunity, the predominant role of genetic factors, and the increasingly effective
immuno-therapeutic possibilities.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
The liver performs a very large number of tasks (i.e., protein
synthesis and metabolism, including the metabolism of carbohy-
drates, lipids, amino acids, and vitamins) that also support the
function of other organs and impacts almost all physiologic sys-
tems. Since large volume of antigen-rich blood is continuously
delivered to the liver from the alimentary tract organs, an essential
function of the liver is to degradate and to remove toxins, exoge-
nous antigens and infectious agents from the periferal blood cir-
culation. For this reason, the immune system developed specialized
mechanisms of immune tolerance able to avoid immune over-
activation but also, viceversa, to switch from a tolerant to aases, Department of Gastro-
via Manzoni 56, 20089 Roz-
All rights reserved.responsive state when necessary [1e6]. It is nowwell accepted that
the liver is a mediator of systemic and local innate and adaptive
immunity and an important site of immune regulation (Fig. 1).
The ﬁrst evidence of the uniqueness of the liver in terms of
immune system control has occurred with the beginning of the
transplant era in the early sixties, when Starzl performed the ﬁrst
human liver transplant [7]. Transplant surgeons noticed that allo-
geneic liver grafts were more tolerant than other allografts such as
kidney, skin, and pancreas, thus suggesting that the liver is biased
towards tolerance rather than an immune-reactive state. Few years
later, two seminal papers showed that animals tolerated more
antigens administered through the portal vein with respect to the
systemic circulation [8], and that the liver allografts were not
rejected in spite of major histocompatibility complex (MHC)
mismatch in animals without immunosuppression [9]. Interest-
ingly, liver transplantation was found to be able to improve the
survival of other organ allografts. Based on these early data, it was
clear that it would have been possible to develop speciﬁc immune
therapies both for breaking or for increasing tolerance by acting on
Fig. 1. A schematic representation of the immune function of the liver. The liver
received continuously large volume of antigen-rich blood from the gastrointestinal
tract. Specialized immune or immune-related cells resident in the liver, can both react
with an alert response to potentially hazardous molecules, but can also dampen their
responsiveness to further stimuli. There is also a continuous crosstalk between the
hepatic immune-related network and the extra-hepatic immune system cells and
organs.
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lying reasons for the unique mechanisms of the liver immune
system and its predominant tolerant state remained unknown until
recently, and further studies are still needed.
Common immune effector mechanisms are known to facilitate
liver injury in the course of liver diseases, one of themajor causes of
morbidity and mortality worldwide. While in acute hepatitis the
insult and the repair are generally well compensated [10], in
chronic hepatitis an ineffective repair promotes the development of
cirrhosis and cancer, which are potentially life threatening for
humans and may require organ transplantation [11,12]. For this
reason, the development of liver cirrhosis and cancer during
chronic liver diseases is the most important problem in our daily
clinical practice. Diverse etiologies can cause liver disease, ranging
from hepatitis virus infections, such as hepatitis C and B virus
[13,14], intoxications to imbalanced diets, including alcohol abuse
and steatosis-related pathology [15,16], or autoimmune liver dis-
eases (ALD) such as autoimmune hepatitis (AIH), primary biliary
cirrhosis (PBC), and primary sclerosing cholangitis (PSC) [17]. Irre-
spective of the causes, a better understanding of the underlying
immune-related mechanisms is mandatory for the design of new
drugs to be used in clinic.
2. Basic mechanisms of immune-mediated liver insult
2.1. Liver anatomy and microanatomy
The liver function to be an immunologic organ is largely ach-
ieved thanks to an unique anatomy and microanatomy [18]. First,
the liver receives both arterial blood through the hepatic arteries
and venous antigen-rich blood from the portal vein, but the
venous circulation is more important from an immunological
point of view because it delivers to the liver very large volume of
antigen-rich blood from the alimentary tract (i.e. stomach, gut,
rectum), and the spleen. Second, in addition to the parenchymal
cells (hepatocytes and cholangiocytes) the liver contains a
plethora of highly specialized non-parenchymal cells that
compose ﬁve structural systems comprising the vascular system,the hepatic lobule, the hepatic sinusoidal system, the biliary sys-
tem and the stroma, each of them playing an important role in the
homeostasis of the innate and adaptive immune system. In
particular, among the non-parenchymal cells there are the liver
sinusoidal endothelial cells that lack the basement membrane to
allow easy transmission of molecules/antigens from blood to liver
parenchyma [19,20], and the hepatic stellate cells that have a
intense crosstalk with the immune system cells [21]. Finally, the
liver contains a complex repertoires of lymphoid and non-
lymphoid cells, key effectors for hepatic immunoregulation and
defense [1,5,6].
2.2. Hepatic non-lymphoid cells
The liver contains specialized cells of myeloid lineage that
comprise Kupffer cells (KC) [22] and dendritic cells [23,24]. Den-
dritic cells are the primary antigen-presenting cells of the liver,
recently found to be of prevalent myeloid origin [25]. It is to note
that also hepatic parenchymal cells such as cholangiocytes can act
as antigen presenting cells [26], thus playing a critical role in the
hepatic immune function. KC are the largest population of
mononuclear phagocytes in the body and already present in the
liver during the fetal development. During liver injury and dis-
eases monocytes are known to rapidly differentiate into mature
cells that are indistinguishable from genuine KC, independently
from the circulating monocytes [27]. The KC strategic position at
the luminal side of the liver sinusoidal endothelium is ideal for
their prime function, that is surveillance and clearance of the
venous portal blood circulation. To maintain the steady state, KC
are able to mount opposite responses to exogenous triggers,
polarizing to M1 or M2 subphenotypes [28]. They can both react
with an alert response to potentially hazardous molecules, but
they can also dampen their responsiveness to further stimuli
when get in contact to the antigen-rich blood from the gut.
Interestingly, KC seems to have a major role in causing loss of
tolerance in PBC [26,29].
2.3. Hepatic lymphoid cells
Liver resident lymphocytes are distinct both in function,
phenotype, and even perhaps developmentally from their coun-
terparts in the peripheral circulation and in other organs. In
particular, they include both conventional (i.e., B cells, CD4þ and
CD8þ T cells, natural killer (NK) cells) and non conventional
lymphoid cells (i.e., gamma delta TCRþ T cells, NK T cells, CD4-
CD8- T cells). Among their liver-speciﬁc functions/phenotypes, it
has been demonstrated that most of the hepatic T cells are
apoptosing peripheral T cells, express the TCR at an intermediate
level and the great majority of them coexpress NK cell markers. In
addition, the percentage of resting T lymphocytes and B cells are
underrepresented in the liver while memory (CD45RB lowþ) and
activated (CD69þ) lymphocytes are overrepresented than naive
cells (CD62L high). Recent quantitative and functional data
showed that the mucosal-associated invariant T (MAIT) cells are a
highly specialized T cell population highly adapted to exert their
immune functions in the vascular network of the liver [30]. Based
on these data, MAIT cells may well play a crucial role in the liver-
speciﬁc immune mechanisms but further studies are still neces-
sary, in particular in patients with ALD. Regulatory T cell (Treg)
populations seem to have an important role in maintaining a
beneﬁcial balance in the liver between immuno-tolerance and
activation. In particular, solid data showed a role of CD4þCD25þ
Treg in the pathogenesis of AIH [31], with clinical implication due
to the possible development of therapeutic approaches based on
Treg function modulation [32]. On the contrary, in PBC Treg seem
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available on Treg in PSC.
3. Loss of immune tolerance and development of
autoimmune liver diseases
ALD can be classiﬁed into two main entities according to the
focus of autoimmune injury, i.e. autoaggression against to hepato-
cyte or to cholangiocyte, and the pattern of inﬂammation
[17,35,36]. Although the ALD are accumulated by the loss of toler-
ance, their clinical phenotypes and the immunological character-
istics differ signiﬁcantly [37e40]. AIH is a quite uniform condition
[40,41], while the autoimmune cholangiopathies comprehends
disorders of the intrahepatic biliary ducts such as PBC [26,39,42],
and of both the intra- and extra-hepatic one, such as PSC [38], or
the immunoglobulin G4-associated cholangitis [43]. There is no
doubt on the autoimmune nature of AIH and PBC, while, on the
contrary, PSC should be considered an immuno-related other than a
classical autoimmune disorder since the lack of some important
criteria necessary to deﬁne it as autoimmune, i.e. the lack of speciﬁc
serum autoantibodies [38]. Although the immunoglobulin G4-
associated cholangitis is a manifestation of the recently discov-
ered idiopathic IgG4-related disease and its pathogenesis is still
largely obscure, its autoimmune nature is suggested by strong
responsiveness to steroids [43]. In addition, Beuers and colleagues
recently showed that speciﬁc B cell responses are pivotal to the
pathogenesis of this disorder since the presence of large amount of
IgG4þ B cell receptor clones [43,44]. Not rarely, the simultaneous
autoaggression against to hepatocytes and to cholangiocytes can
cause “overlap syndromes” between PBC and AIH, or PSC and AIH
[45].
AIH and PBC have a strong female preponderance, while PSC is
more frequent in male. AIH and PSC affect all ages and races, while
PBC is rarely seen in children. Immunosuppression is an effective
treatment for AIH while PBC and PSC are currently treated with
ursodeoxycholic acid, a not toxic an choleretic bile bile acid [37e
40]. PBC is characterized by immune cell activation and damage
of cholangiocytes of small and medium bile ducts, leading to
chronic cholestasis and ultimately hepatic ﬁbrogenesis and liver
failure in one third of patients within 10 years from diagnosis [39].
In patients with PSC, both intra- and extra-hepatic bile ducts can be
damaged and the disease is characterized by a progressive forma-
tion and accumulation of periductular ﬁbrosis, whichmay resulting
in bile duct strictures [38].
3.1. Genetics factors
Different ALD have different and multifactorial pathogenesis,
with genetic/epigenetic and environmental factors interplaying to
determine disease onset and progression. While our knowledge of
the nature and quantiﬁcation of environmental factors is still very
limited [46,47], the genetic architecture of PBC and PSC is now
better known thanks to a number of recent genome wide associa-
tion studies [48e59]. A number of loci have been found to be
associated with these autoimmune cholangiopathies, including
HLA (consistently the strongest genetic associations) and immune-
related non-HLA genes such as IL2, IL12A, IL12RB, STAT4 and CTLA4.
Interestingly, it has been reported a shared genetic architecture of
PSC and PBC with various other immune-related conditions.
However, disease-speciﬁc studies are still required to understand
the real contribution of these genetic risk factors for the develop-
ment of each disease and to develop novel therapies. On the con-
trary to PBC and PSC, genetic associations with HLA and non-HLA
genes have been reported in AIH but no large genome wide asso-
ciation studies are still available [40].3.2. Diagnostic biomarkers
Over the last decade, our approach to diagnose each of the ALD
is not signiﬁcantly changed, consisting ﬁrst in the exclusion of other
causes of liver damage, such as viral, toxic, alcoholic, genetic,
metabolic or non-alcoholic fatty liver disease, and then in the
evaluation of speciﬁc clinical, biochemical, histopathological, and
cholangiographic features speciﬁc [38e40]. In general, the diag-
nosis is based on a combination of diagnostic features to obtain a
higher sensitivity and speciﬁcity.
Serum autoantibodies are the diagnostic hallmarks for PBC and
AIH (while no speciﬁc autoantibodies were reported in PSC) and
seem to allow the identiﬁcation of subsets of patients with different
prognosis [60e64]. Serum hallmarks of PBC patients are the pres-
ence of antimitochondrial antibodies and some PBC-speciﬁc anti-
nuclear antibodies such as anti-gp210 and anti-sp100 [60,63e65].
Antimitochondrial antibodies are detected in up to 95% of PBC
serum samples and their target antigens localized to the inner
membrane of the mitochondria; in particular to the E2 subunits of
the 2-oxo-acid dehydrogenase multienzyme family, the pyruvate
dehydrogenase complex (PDC), the branched-chain 2-oxo acid
dehydrogenase complex (BCOADC) and 2-oxoglutarate dehydro-
genase complex (OGDC). Two types of AIH can be recognized based
on serology: type 1 AIH, characterized by the presence of anti-
nuclear and/or anti-smooth muscle antibodies and type 2 AIH
positive for anti-liver kidney microsomal type 1 antibody. While
the nuclear and smooth muscle autoantigens are poorly deﬁned,
the cytochrome P450IID6, a member of the cytochrome P450
family of hepatic detoxifying enzymes, is the well known antigens
for anti-liver kidney microsomal type 1 antibody.
3.3. Liver-gut axis
The human intestinal microﬂora is considered to be very
important in the etiopathogenesis of PSC, mainly because up to 80%
of patients with PSC have concomitant inﬂammatory bowel dis-
eases at some point in their lifetime and about 4% of patients with
UC develops PSC [38]. A number of other evidences suggest that
intestinal bacteria is a key factor involved in PSC liver inﬂammation
[66]. First, many genes involved in innate immune pathways are
increasingly expressed in PSC, and in particular at the late stages of
disease. Second, although the strong genetic association with
HLA in PSC does not predispose to IBD, a number of non-HLA ge-
netic variants related to mucosal immunity (i.e., macrophage-
stimulating-1, IL-2/IL-2 receptor alpha, and caspase-recruitment
domain-9) are shared between PSC and IBD [59,67]. Third, the
bile of PSC patients often contains enteric bacteria such as E. coli
and Candida [68]. Finally, b-tubulin, the autoantigen of the PSC-
associated serum atypical perinuclear antineutrophil cytoplasmic
antibodies is known to cross-react with the bacterial cytoskeletal
protein FtsZ [69,70]. Thus, a clinically relevant problem that war-
rants further investigation in the near future is the. Further studies
are required to identify the bacterial species that trigger PSC and
perinuclear antineutrophil cytoplasmic antibodies and to under-
stand if modulation of gut microbiota might aid in the treatment of
this disease.
In PBC, the observations that AMA cross-react with bacterial
components, such as E. coli, b-galactosidase of Lactobacillus del-
brueckii proteins [71e73] is considered a key event for its early
pathogenesis and suggests an important guteliver association [66].
3.4. Biliary epithelium
The biliary epithelium is highly heterogeneous, with regard
to morphological and phenotypical characteristics [74]. In
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angiocytes have different secretory, apoptotic and proliferative
responses. PBC and PSC, the two most common cholangiopathies
observed in the biliary epithelium, are characterized by chol-
angiocytes proliferation/apoptosis, inﬂammation and ﬁbrosis of
different sized bile ducts, in other words by a “biliary epithelitis”
[26,75].
The biliary and gut epithelia are contiguous components of
the mucosa and have common barrier functions and mechanisms
to defend from pathogens. This is of particular interest to un-
derstand the pathogenetic mechanisms underlying the devel-
opment of PSC [38]. For an in-depth discussion of the role of
biliary epithelium and a biliary epithelitis in PSC genetics we
refer the reader elsewhere [Trivedi et al. 2013]. With regard to
the PBC pathogenesis, it is instructive to consider the large
number of similarities between this autoimmune cholangiopathy
and Sjogren syndrome, an autoimmune disease due to aggression
to salivary and lachrymal ducts [76e100]. Indeed, both diseases
frequently overlap with each other, with most of PBC patients
suffering from sicca and some of them have a classic Sjogren’s
syndrome. Both PBC and Sjogren’s syndrome are characterized by
inﬂammation of target epithelium, a condition that can named
“autoimmune epithelitis”.
The current proposed immunopathogenesis of PBC and Sjog-
ren’s syndrome suggest, as a triggery event, that environmental
factors cause biliary or salivary/lachrimatory epithelial cell
apoptosis, thus contributing to tolerance loss to autoantigens
possibly not protected by posttranslational modiﬁcation (PDC-E2),
or exposed on the apoptotic blebs (SSA and SSB). It is also known
that biliary epithelial salivary/lachrimatory cells concur to the
autoimmune process by expressing adhesion molecules, HLA class
II, and cytokines. Recent evidences from large genome wide asso-
ciation studies both in PBC and in Sjogren’s syndrome suggest that
common inﬂammatory genes may have a role in these disease
[53,101,102]. In the future it will become critical elements to dissect
the genetic predispositions for both diseases and in particular the
molecular basis of effector mechanisms, also to develop new
therapies.
4. Concluding remarks
Evidences supporting the concept that the liver is a lymphoid
organ are available since the early sixties, but only in the last few
years we started to dissect the underlying mechanisms that
makes the liver an unique organ in the human body for its ability
to balance between immune tolerance and overreaction. This
critical and complex function of the liver is obtained thanks to a
peculiar anatomy and microanatomy, unique features of hepatic
parenchymal cells and a large number of resident immune and
immune-related cells. One of the area which is more beneﬁting
from these advances, it is that related to ALD, liver diseases due
to a loss of tolerance. Liver autoimmunity is indeed a great
paradox for an organ with peculiar tolerizing properties. Growing
amount of evidences are dissecting the complex mechanisms
which coordinate immune responses between the liver and gut,
and the role of gut bacteria in ALD. As for many other complex
diseases, genome wide association studies are providing impor-
tant information on the ethiopathogenesis of ALD. Of course, the
accumulating knowledge from these generic studies needs to be
conﬁrmed and explored in the context of functional studies with
the ultimate goal of developing novel therapeutic approaches for
ALD. There is no doubt that we are witnessing the birth of a new
era of clinical opportunities, but the real challenge is now to
transfer these “basic” knowledge to the clinical arena with a
beneﬁcial impact to our patients.References
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